Full Press Release Details
IDE196 Program Updates Targeting Initiation of Potentially Registration Enabling Phase 2 Single Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020.
IDYA
IDE196 Program Updates Targeting Initiation of Potentially Registration Enabling Phase 2 Single Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
Key Takeaway: IDE196 Program Updates Targeting Initiation of Potentially Registration Enabling Phase 2 Single Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma